Genmab Discontinues Phase III Development of Acasunlimab Lung Cancer Asset Previously Ditched by BioNTech

Genmab is ending development of acasunlimab, a bispecific PD-L1/4-1BB antibody in Phase III trials for non-small cell lung cancer (NSCLC) and other solid tumors1 3 4

The decision follows a strategic pipeline review focusing on higher-value late-stage assets like Epkinly, petosemtamab, and Rina-S, amid a competitive landscape assessment1 3 5

BioNTech opted out of further development in 2024, leaving Genmab with full rights1 3

CEO Jan van de Winkel stated the clinical data was encouraging but resources will prioritize programs with greater patient and shareholder benefit1 5

The move does not affect Genmab’s 2025 financial guidance; analysts view it positively, citing $8B peak sales potential for lead assets1 3 4

Sources:

1. https://www.clinicaltrialsarena.com/news/genmab-shelves-phase-iii-lung-cancer-candidate/

3. https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49615613/genmab-prunes-pipeline-sharpens-focus-on-late-stage-cancer-assets

4. https://trial.medpath.com/news/5d888d784e110202/genmab-discontinues-phase-iii-lung-cancer-bispecific-antibody-acasunlimab-to-focus-on-late-stage-pipeline

5. https://www.fiercebiotech.com/biotech/jj-genmab-discard-eczema-cancer-therapies-over-uninspiring-clinical-data

Sources:

Leave a Reply Cancel reply